Meanwhile, outside analyses have set a cost-effective price for Kymriah between $600,000 and $750,000, he added.

他还说，与此相比，外界分析认为，Kymriah的价格介于60万美元到75万美元较为合理。

"Recognising our responsibility we set the price below that level," said Strigini.

“我们深知责任在身，所以没将价格定得那么高，” 斯蒂格尼说。

Most patients who fit the criteria for treatment would likely be covered by insurance, since they are under 25 and would either be on their parents' insurance or covered by government-sponsored Medicaid, a Novartis spokesman said.

诺华的发言人表示，大多数符合条件的患者很可能会用保险支付费用，因为他们都未满25岁，所以会使用父母的保险或者政府资助的医疗补助。

The treatment was pioneered by Carl June at the University of Pennsylvania.

该疗法由宾夕法尼亚大学的卡尔?琼开创。

Its most high-profile patient is Emily Whitehead, now 12.

今年12岁的艾米丽?怀特海是该疗法最为人熟知的一位患者。

Six years ago, she was the first child to receive what was widely considered a risky treatment.

6年前，艾米丽成为首个接受当时社会普遍认为具有风险的Kymriah治疗的儿童。

She has been cancer-free ever since.

不过，Kymriah治好了她的癌症。

【首个白血病治疗基因疗法在美获批】相关文章：

★ 权游最终季：谁是最后赢家？粉丝一起来猜猜猜

★ 九款搞怪创意的台灯

★ 为什么抱臂能帮助抑制疼痛

★ 分手后把前任从照片上P掉，这个服务可以有

★ 头发乱蓬蓬的小男孩

★ 讲讲你见过最差劲的老师

★ 老板的小小举动温暖了我的心

★ 情绪一点就炸：被拒绝之前，我先拒绝你

★ Airbnb被爆房东偷拍房客

★ 研究发现：互联网普及与处方药滥用呈正相关